ArticleJournal of breast cancer2026
Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.
Article in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-term outcome comparisons between invasive lobular carcinoma (ILC) and invasive carcinoma of no special type (NST, historically referred to as invasive ductal carcinoma) remain inconsistent, particularly in patients with low-proliferative hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) disease. This study evaluated the long-term outcomes of ILC and NST in a pathologically defined, low-proliferative, HR+/HER2- (luminal A-like) cohort.
methodsThis retrospective, single-institution study included patients with HR+/HER2- breast cancer and Ki-67 ≤ 20% who underwent surgery between 2008 and 2015. Patients with mixed histopathology, those who underwent palliative surgery, or those who received neoadjuvant chemotherapy were excluded. Survival was analyzed using the Kaplan-Meier method and multivariable Cox regression. A secondary 24-month landmark analysis included patients who were alive, disease-free, under observation, and receiving endocrine therapy 24 months after surgery.
resultsAmong 3,439 patients, 3,156 had NST and 283 had ILC. Compared with NST, ILC was associated with a higher rate of synchronous bilateral breast cancer, a more advanced pathological stage, and a lower nuclear grade. In the comprehensive cohort, breast cancer-specific survival did not differ significantly (log-rank
conclusionIn this low-proliferative HR+/HER2- cohort, ILC showed less favorable unadjusted long-term DFS and DMFS than NST, but these differences were attenuated and were no longer statistically significant after adjustment for measured clinicopathological characteristics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.